Theme booklet of neurology
The current issue of “theme booklet of neurology” reports on Atrial Fibrillation NETwork (AFNET), get your access here (german only).
Unkategorisiert
EAST-AFNET 4 @ ESC 2022
The newest subanalysis of the EAST-AFNET 4 study will be presented at this year’s ESC congress 2022 in Barcelona:
Subanalysis of the EAST – AFNET 4 trial: Patients with AF and high comorbidity burden benefit from early rhythm control
Subanalysis of the EAST – AFNET 4 trial: Patients with AF and high comorbidity burden benefit from early rhythm control
Smart in OAC – AFNET 9
The design paper was successfully published in “Frontiers in cardiovascular medicine”. Get access to the paper here.
EAST-AFNET 4 @ EHRA 2022
The latest results of the EAST-AFNET 4 study will be presented at this year’s EHRA congress 2022:
Late Breaking Clinical Trials II
Atrial fibrillation – News on ablation and sex differences
Monday, 4th of April 2022 | 6:15 pm – 7:15 pm (CEST), Room 1
Session chaired by Tatjana Potpara
More information
EAST – AFNET 4 trial: Patients with first diagnosed atrial fibrillation (AF) benefit from early rhythm control
Early rhythm control is useful in patients with atrial fibrillation regardless of the AF pattern. Patients with first diagnosed atrial fibrillation benefit from early rhythm control therapy comparably to patients with paroxysmal or persistent AF. This is the result of a subgroup analysis of the EAST – AFNET 4 trial that was presented by Professor Andreas Goette, St. Vincenz Hospital Paderborn, at the American Heart Association (AHA) congress on 14.11.2021 in Boston [1].
Early rhythm control improves outcomes in patients with asymptomatic atrial fibrillation
Asymptomatic patients with atrial fibrillation (AF) benefit from early rhythm control therapy comparably to symptomatic patients. This is the result of a subgroup analysis of the EAST – AFNET 4 trial that was presented by Professor Stephan Willems, Asklepios Hospital St. Georg, Hamburg, at the annual congress of the European Society of Cardiology (ESC) on 27.08.2021 [1] and published in the European Heart Journal [2].
EAST-AFNET 4 @ ESC Congress 2021
The latest results of the EAST – AFNET 4 study will be presented at this year’s ESC Congress 2021 (streamed live):
Late Breaking Science in Arrhythmias
Benefit of early rhythm control therapy in patients with asymptomatic AF -insights from EAST-AFNET 4
Friday, 27th of August 2021 | 10.30am – 11:15am (CEST)
Presented by Prof. Dr. Stephan Willems
EAST-AFNET 4 @ ESC Congress 2021
Die neuesten Ergebnisse der EAST-AFNET 4 Studie werden auf dem diesjährigen ESC Congress 2021 als Live-Stream präsentiert:
Late Breaking Science in Arrhythmias
Benefit of early rhythm control therapy in patients with asymptomatic AF -insights from EAST-AFNET 4
27.08.2021 | 10:30 – 11:15 Uhr (CEST)
Präsentiert von Prof. Dr. Stephan Willems
Patients with atrial fibrillation and heart failure benefit from early rhythm control
A subgroup analysis of the EAST – AFNET 4 study population revealed: Early initiation of rhythm control therapy is associated with clinical benefit in patients with heart failure and recently diagnosed atrial fibrillation. The new findings were presented by Dr. Andreas Rillig, UKE Hamburg, at the HRS congress on 30.07.2021 [1], [2].